Armin Schueler

Mr. Armin Schueler

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Céleste LebbéCéleste Lebbé
Céleste Lebbé
CDCaroline Dutriaux
Caroline Dutriaux
TLThierry Lesimple
Thierry Lesimple
WKWillem Kruit
Willem Kruit
JKJoseph Kerger
Joseph Kerger
BDBrigitte Dréno
Brigitte Dréno
This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM1 NRAS-mutated cutaneous melanoma were randomized 2:1 to pimasertib (60 mg; oral twice-daily) or DTIC (1000 mg/m2; intravenously) on Day 1 of each 21-day cycle. Patients progressing on DTIC could crossover to pimasertib. Primary endpoint: investigator-assessed progression-free survival (PFS); secondary endpoints: overall survival (OS), objective response rate (ORR), quality of life (QoL), and safety. Overall, 194 patients were randomized (pimasertib n = 130, DTIC n = 64), and 191 received treatment (pimasertib n = 130, DTIC n = 61). PFS was significantly improved with pimasertib versus DTIC (median 13 versus 7 weeks, respectively; hazard ratio (HR) 0.59, 95% confidence interval (CI) 0.42–0.83; p = 0.0022). ORR was improved with pimasertib (odds ratio 2.24, 95% CI 1.00–4.98; p = 0.0453). OS was similar between treatments (median 9 versus 11 months, respectively; HR 0.89, 95% CI 0.61–1.30); 64% of patients receiving DTIC crossed over to pimasertib. Serious adverse events (AEs) were more frequent for pimasertib (57%) than DTIC (20%). The most common treatment-emergent AEs were diarrhea (82%) and blood creatine phosphokinase (CPK) increase (68%) for pimasertib, and nausea (41%) and fatigue (38%) for DTIC. Most frequent grade ≥3 AEs were CPK increase (34%) for pimasertib and neutropenia (15%) for DTIC. Mean QoL scores (baseline and last assessment) were similar between treatments. Pimasertib has activity in NRAS-mutated cutaneous melanoma and a safety profile consistent with known toxicities of MEK inhibitors. Trial registration: ClinicalTrials.gov, NCT01693068.

23 August 2020 in Pharmaceutical Statistics
Verified
Journal Article
Open access
PDF file
RRRobin Ristl
Robin Ristl
NBNicolás M Ballarini
Nicolás M Ballarini
HGHeiko Götte
Heiko Götte
ASArmin Schueler
Armin Schueler
MPMartin Posch
Martin Posch
FKFranz König
Franz König
SUMMARY: In the analysis of survival times, the logrank test and the Cox model have been established as key tools, which do not require specific distributional assumptions. Under the assumption of proportional hazards, they are efficient and their results can be interpreted unambiguously. However, delayed treatment effects, disease progression, treatment switchers or the presence of subgroups with differential treatment effects may challenge the assumption of proportional hazards. In practice, weighted logrank tests emphasizing either early, intermediate or late event times via an appropriate weighting function may be used to accommodate for an expected pattern of non‐proportionality. We model these sources of non‐proportional hazards via a mixture of survival functions with piecewise constant hazard. The model is then applied to study the power of unweighted and weighted log‐rank tests, as well as maximum tests allowing different time dependent weights. Simulation results suggest a robust performance of maximum tests across different scenarios, with little loss in power compared to the most powerful among the considered weighting schemes and huge power gain compared to unfavorable weights. The actual sources of non‐proportional hazards are not obvious from resulting populationwise survival functions, highlighting the importance of detailed simulations in the planning phase of a trial when assuming non‐proportional hazards.We provide the required tools in a software package, allowing to model data generating processes under complex non‐proportional hazard scenarios, to simulate data from these models and to perform the weighted logrank tests.

21 December 2021 in Biometrical Journal
Verified
Journal Article
Closed access
PDF file
PGPranab Ghosh
Pranab Ghosh
RRRobin Ristl
Robin Ristl
FKFranz König
Franz König
MPMartin Posch
Martin Posch
CJChristopher Jennison
Christopher Jennison
CMCyrus Mehta
Cyrus Mehta

5 August 2022 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
KPKristyn Pantoja
Kristyn Pantoja
SLShankar Lanke
Shankar Lanke
AMAlain Munafo
Alain Munafo
AVAnja Victor
Anja Victor
CHChristina Habermehl
Christina Habermehl
KGKosalaram Goteti
Kosalaram Goteti
One of the objectives of oncology phase I dose‐escalation studies has been to determine the maximum tolerated dose (MTD). Although MTD is no longer set as the dose for further development in contemporary oncology drug development, MTD determination is still important for informing the therapeutic index. Bayesian adaptive model‐based designs are becoming mainstream in oncology first‐in‐human trials. Herein, we illustrate via simulations the use of systemic exposure in Bayesian adaptive dose–toxicity models to estimate MTD. We extend traditional dose–toxicity models to incorporate pharmacokinetic exposure, which provides information on exposure–toxicity relationships. We pursue dose escalation until the maximum tolerated exposure (corresponding to the MTD) is reached. By leveraging pharmacokinetics, dose escalation considers exposure and interindividual variability on a continuous rather than discrete domain, offering additional information for dose‐escalation decisions. To demonstrate this, we generated 1000 simulations (starting dose of 1/25th the reference dose and six dose levels) for several different scenarios. Both rule‐based and model‐based designs were compared using metrics of potential safety, accuracy, and reliability. The mean results over simulations and different toxicity scenarios showed that model‐based designs were better than rule‐based methods and that exposure–toxicity model‐based methods have the potential to valuably complement dose–toxicity model‐based methods. Exposure–toxicity model‐based methods had decreased underdose risk accompanied by a relatively smaller increase in overdose risk, resulting in improved net reliability. MTD estimation accuracy was compromised when exposure variability was large, emphasizing the importance of appropriate control of pharmacokinetic variability in phase I dose‐escalation studies.

21 January 2022 in Pharmaceutical Statistics
Verified
Journal Article
Closed access
PDF file
HGHeiko Götte
Heiko Götte
MKMarietta Kirchner
Marietta Kirchner
JKJohannes Krisam
Johannes Krisam
AAArthur Allignol
Arthur Allignol
FLFrancois‐Xavier Lamy
Francois‐Xavier Lamy
MKMeinhard Kieser
Meinhard Kieser

1 August 2020 in Clinical Therapeutics
Verified
Journal Article
Open access
JLJason Lickliter
Jason Lickliter
RKRadmila Kanceva
Radmila Kanceva
EVEmmanuelle Vincent
Emmanuelle Vincent
ASArmin Schueler
Armin Schueler
EHEleanor Harrison-Moench
Eleanor Harrison-Moench
PGPaul Griffin
Paul Griffin
Purpose: MSB11455 is a proposed biosimilar to the reference pegfilgrastim (Neulasta (R)). This pivotal equivalence study (NCT03251248) assessed the pharmacokinetic and pharmacodynamic equivalence of MSB11455 to the reference product. Methods: This 2-way, 2-sequence, group- sequential, crossover study was conducted in healthy subjects. Subjects received a single subcutaneous dose of MSB11455 or the reference product (both 6 mg/0.6 mL) on Day 1 of each study period. Pharmacokinetic and pharmacodynamic (absolute neutrophil count; ANC) samples were taken predose and up to day 16 post-dose. Non-compartmental parameters were calculated. Immunogenicity samples were taken pre-dose and up to day 84 after the first dose. Safety was assessed throughout the study. Findings: A total of 292 subjects were randomized to therapy and treated; 244 received both treatments. For all primary pharmacokinetic and pharmacodynamic parameters, 90% repeated confidence intervals of geometric means ratio of MSB11455 to the reference product were within the pre-defined equivalence range (80.00%-125.00%) for AUC(0-infinity) (96.59-112.82); AUC(0-last) (97. 2 9 -11 3.96), C-max (97.13-114.99), maximum observed effect on ANC (98.74-102.39), and area under the effect-time curve from time zero to time to last quantifiable concentration (97.30-100.23). Safety, tolerability, and immunogenicity were comparable between treatments. No filgrastim-specific neutralizing antibodies were detected with either treatment sequence. (C) 2020 The Author(s). Published by Elsevier Inc.